Trial: 202102196

A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations



Principal Investigator

Cluster, Andrew

Disease Site

Brain and Nervous System

Learn more about this study at: